ZA202206666B - Crystal form for treating liver disease and use thereof - Google Patents

Crystal form for treating liver disease and use thereof

Info

Publication number
ZA202206666B
ZA202206666B ZA2022/06666A ZA202206666A ZA202206666B ZA 202206666 B ZA202206666 B ZA 202206666B ZA 2022/06666 A ZA2022/06666 A ZA 2022/06666A ZA 202206666 A ZA202206666 A ZA 202206666A ZA 202206666 B ZA202206666 B ZA 202206666B
Authority
ZA
South Africa
Prior art keywords
crystal form
liver disease
treating liver
treating
disease
Prior art date
Application number
ZA2022/06666A
Inventor
Gao Zhongqiang
Guo Weibo
He Kaimin
Tian Dan
Zhang Dengke
Jin Weili
Zhang Haifeng
Sun Jiangkai
Original Assignee
Xian Xintong Pharmaceutical Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010376938.9A external-priority patent/CN112028940B/en
Priority claimed from CN202010376833.3A external-priority patent/CN112010905B/en
Priority claimed from CN202010391424.0A external-priority patent/CN112047990B/en
Application filed by Xian Xintong Pharmaceutical Res Co Ltd filed Critical Xian Xintong Pharmaceutical Res Co Ltd
Publication of ZA202206666B publication Critical patent/ZA202206666B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20008Constructional details of analysers, e.g. characterised by X-ray source, detector or optical system; Accessories therefor; Preparing specimens therefor
    • G01N23/2005Preparation of powder samples therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/207Diffractometry using detectors, e.g. using a probe in a central position and one or more displaceable detectors in circumferential positions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2022/06666A 2020-05-07 2022-06-15 Crystal form for treating liver disease and use thereof ZA202206666B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010376938.9A CN112028940B (en) 2020-05-07 2020-05-07 Tenofovir phosphate crystal form and preparation and application thereof
CN202010376833.3A CN112010905B (en) 2020-05-07 2020-05-07 Paradifovir mesylate crystal form and application thereof
CN202010391424.0A CN112047990B (en) 2020-05-11 2020-05-11 Cytarabine prodrug MB07133 crystal form and application thereof
PCT/CN2020/130060 WO2021223398A1 (en) 2020-05-07 2020-11-19 Crystal form for treating liver disease and use thereof

Publications (1)

Publication Number Publication Date
ZA202206666B true ZA202206666B (en) 2023-09-27

Family

ID=78467750

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/06666A ZA202206666B (en) 2020-05-07 2022-06-15 Crystal form for treating liver disease and use thereof

Country Status (2)

Country Link
WO (1) WO2021223398A1 (en)
ZA (1) ZA202206666B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100439387C (en) * 2002-10-31 2008-12-03 美达贝斯制药有限公司 Novel cytosine monophosphate medicine precursor
RU2006138907A (en) * 2004-06-08 2008-07-20 Метабазис Терапеутикс SYNTHESIS OF COMPLEX CYCLIC ETHERS USING LEWIS ACID
CN101475594B (en) * 2009-02-06 2012-05-30 廖国超 Liver targeted antivirus precursor medicament annular phosphoester and use thereof
AU2013257951A1 (en) * 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
CN102827206B (en) * 2012-09-17 2015-06-17 西安新通药物研究有限公司 Pradefovir crystal
CN103333209B (en) * 2013-07-05 2015-09-30 西安新通药物研究有限公司 The new crystal of tynofovir prodrug (HTS)
CN104710477A (en) * 2013-12-16 2015-06-17 安徽贝克联合制药有限公司 Tenofovir cyclic phosphonate compound and pharmaceutically acceptable salt thereof, and preparation methods and applications thereof
KR20230070330A (en) * 2014-07-10 2023-05-22 레플리코르 인코포레이티드 Methods for the treatment of hepatitis b and hepatitis d virus infections
CN107540710B (en) * 2016-06-24 2020-10-16 浙江柏拉阿图医药科技有限公司 Liver delivery antiviral prodrug nucleoside cyclic phosphate ester compound and application thereof

Also Published As

Publication number Publication date
WO2021223398A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
IL279688A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
IL288061A (en) Compounds and methods for the treatment of covid-19
EP4010080C0 (en) Heterocyclic compounds for use in the treatment of cancer
SG11202007226UA (en) Methods and compositions for treating sleep apnea
IL283938A (en) Compounds and their use for the treatment of α1-antitrypsin deficiency
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3858353A4 (en) Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof
IL285989A (en) Method for treating fatty liver disease and/or steatohepatitis
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
IL285197A (en) Methods and compositions for treating sleep apnea
IL276713A (en) Variant cd3-binding domains and their use in combination therapies for the treatment of disease
ZA202100703B (en) Compositions and methods for treating inflammasome related diseases or conditions
IL292221A (en) Compositions and methods for treating liver disease
DK3860990T3 (en) Inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of cancer
IL282251A (en) Compositions and methods for treatment of liver disease
IL290770A (en) Compounds and methods for treating oxalate-related diseases
IL289309A (en) Methods and materials for treating huntington’s disease
DK3937948T3 (en) Phytoecdysones and derivatives thereof for use in the treatment of neuromuscular diseases
ZA202206666B (en) Crystal form for treating liver disease and use thereof
IL274007A (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
PL3810128T3 (en) Compositions for treating and/or preventing protein-aggregation diseases
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
ZA202107235B (en) Compositions and methods for treating ocular disease